Gaetano Bertino

Prof. Gaetano Bertino


Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Gastroenterology
Verified
Journal Article
Closed access
VCVincenza Calvaruso
Vincenza Calvaruso
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
ICIrene Cacciola
Irene Cacciola
SPSalvatore Petta
Salvatore Petta
SMSalvatore Madonia
Salvatore Madonia
FPF. Pulvirenti
F. Pulvirenti

1 August 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
CCCiro Celsa
Ciro Celsa
VCVincenza Calvaruso
Vincenza Calvaruso
SPSalvatore Petta
Salvatore Petta
Irene CacciolaIrene Cacciola
Irene Cacciola
CCCalogero Cammà
Calogero Cammà

15 November 2012 in BMC Surgery
Verified
Journal Article
Open access
PDF file
MUMario Uccello
Mario Uccello
Giulia MalaguarneraGiulia Malaguarnera
Giulia Malaguarnera
Francesco BasileFrancesco Basile
Francesco Basile
Velia D'AgataVelia D'Agata
Velia D'Agata
MMMichele Malaguarnera
Michele Malaguarnera
Antonio BiondiAntonio Biondi
Antonio Biondi
Background: Colorectal cancer represents the most common malignancy of the gastrointestinal tract. Owing to differences in dietary habits and lifestyle, this neoplasm is more common in industrialized countries than in developing ones. Evidence from a wide range of sources supports the assumption that the link between diet and colorectal cancer may be due to an imbalance of the intestinal microflora.Discussion: Probiotic bacteria are live microorganisms that, when administered in adequate amounts, confer a healthy benefit on the host, and they have been investigated for their protective anti-tumor effects. In vivo and molecular studies have displayed encouraging findings that support a role of probiotics in colorectal cancer prevention.Summary: Several mechanisms could explain the preventive action of probiotics against colorectal cancer onset. They include: alteration of the intestinal microflora; inactivation of cancerogenic compounds; competition with putrefactive and pathogenic microbiota; improvement of the host’s immune response; anti-proliferative effects via regulation of apoptosis and cell differentiation; fermentation of undigested food; inhibition of tyrosine kinase signaling pathways.

16 October 2007 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
SNSergio Neri
Sergio Neri
DPDavide Pulvirenti
Davide Pulvirenti
MMMariano Malaguarnera
Mariano Malaguarnera
BCBruno M. Cosimo
Bruno M. Cosimo
GBGaetano Bertino
Gaetano Bertino
PCPietro Castellino
Pietro Castellino

1 July 2014 in Annals of Hepatology
Verified
Journal Article
Open access
ATAdriana Toro
Adriana Toro
AMAhmed-Emad Mahfouz
Ahmed-Emad Mahfouz
AAAnnalisa Ardiri
Annalisa Ardiri
MMMariano Malaguarnera
Mariano Malaguarnera
Giulia MalaguarneraGiulia Malaguarnera
Giulia Malaguarnera
ICIsidoro Di Carlo
Isidoro Di Carlo
Hepatic cavernous hemangioma accounts for 73% of all benign liver tumors with a frequency of 0.4-7.3% at autopsy and is the second most common tumor seen in the liver after metastases. Patients affected by hemangioma usually have their tumor diagnosed by ultrasound abdominal examination for a not well defined pain, but pain persist after treatment of the hemangioma. The causes of pain can be various gastrointestinal pathologies including cholelithiasis and peptic ulcer disease.The malignant trasformation is practically inexistent. Different imaging modalities are used to diagnosis liver hemangioma including ultrasonography, computed tomography (CT), magnetic resonance (MR) imaging, and less frequently scintigraphy, positronemission tomography combined with CT (PET/CT) and angiography. Imaging-guided biopsy of hemangioma is usually not resorted to except in extremely atypical cases. The right indications for surgery remain rupture, intratumoral bleeding, Kasabach-Merritt syndrome and organ or vessels compression (gastric outlet obstruction, Budd-Chiari syndrome, etc.) represents the valid indication for surgery and at the same time they are all complications of the tumor itself. The size of the tumor do not represent a valid indication for treatment. Liver hemangiomas, when indication exist, have to be treated firstly by surgery (hepatic resection or enucleation, open, laproscopic or robotic), but in the recent years other therapies like liver transplantation, radiofrequency ablation, radiotherapy, trans-arterial embolization, and chemotherapy have been applied.

1 August 2012 in Seminars in Oncology
Verified
Journal Article
Closed access
GBGaetano Bertino
Gaetano Bertino
AAAnnalisa Ardiri
Annalisa Ardiri
MMMichele Malaguarnera
Michele Malaguarnera
Giulia MalaguarneraGiulia Malaguarnera
Giulia Malaguarnera
NBNicoletta Bertino
Nicoletta Bertino
GCGiuseppe Stefano Calvagno
Giuseppe Stefano Calvagno